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Abstract
Although access to antiretroviral therapy (ART) for the treatment of HIV has increased during the last decade, many 
patients are still in need of treatment. With limited funds to provide ART to millions of patients worldwide, there is a 
need for alternative ways to scale up ART in resource limited settings. This review provides an overview of 
pharmacokinetic, safety and efficacy studies of generic and reduced dose ART. The production of generic ART has 
greatly influenced the decline in drug prices and the increased in ART access. Generic ART has good pharmacokinetic 
profile, safety and efficacy. Toxicity is however the main cause for ART discontinuation. Several dose reduction studies 
have shown adequate pharmacokinetic parameters and short term efficacy with reduced dose ART. Ethnicity may 
affect drug metabolism; several pharmacokinetic studies have confirmed higher plasma ART concentration in Asians. 
Randomized efficacy trial of reduced versus standard ART is warranted.
Introduction
In 2008, an estimated 33.4 million adults and children
were living with HIV worldwide [1], most of whom were
from low and middle income countries, and 9.6 million
people were in need of antiretroviral treatment (ART) [2].
However, 5.5 million people (58%) had no access to treat-
ment. Even though the great majority of HIV infected
people live in Sub-Saharan Africa, 4.7 million HIV
infected people are living in Asia [1]. The ART coverage
in East, South and South-East Asia was only 37% in 2008
[3]. Although this is an increase compared to the 29% in
2007, the scaling up of antiretroviral therapy is still slow.
This review will focus on two important ways of achiev-
ing ART scale up in resource-limited settings: safe and
effective generic ART, and dose reduction of ART.
Generic Antiretroviral Therapy
In 2001 the World Health Organization (WHO) initiated
the prequalification of priority medicines to make these
available to millions of patients in need in resource-lim-
ited settings. In 2004, the U.S. Food and Drug Adminis-
tration (FDA) launched a program to ensure that HIV
patients being served by the President's Emergency Plan
for AIDS Relief (PEPFAR) would receive safe, effective
and quality manufactured ART. This new initiative
included an expedited review process, and a strong
encouragement for manufacturers worldwide to submit
U.S. marketing applications for previously approved anti-
retroviral therapies, even if there was still a patent or
exclusivity market protection for the product in the U.S.
Currently, the FDA has given tentative approval to 107
generic antiretroviral drugs [4] which gives generic man-
ufacturers the opportunity to produce safe, effective and
good quality antiretroviral therapy combinations without
having to face patent claims.
The introduction of generic fixed dose combination
(FDC) antiretroviral therapy by companies in India and
Thailand has significantly increased the access to treat-
ment in many resource limited countries and is a major
contributing factor to the unprecedented drop in ART
prices. Between 2004 and 2008 the drug prices for first
line regimens declined by 48%, and resulted in sustained
scale up of treatment programs, transaction volume
growth and competition between a growing number of
drugs prequalified by the WHO. The decline in prices
between 2004 and 2008 for second line treatment can
also be attributed to the prequalification of the generic
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alternatives for abacavir (ABC), lopinaivir/ritonavir
(LPV/r) and tenofovir (TDF) [3]. However, in 2009, the
prices for second line regimens were still high in coun-
tries where few or no prequalified generic alternatives are
available.
Pharmacokinetics of generic ART
In a healthy volunteer study, the pharmacokinetic (PK)
parameters of the generic FDC of d4T/3TC/NVP was
compared to PK parameters of the three branded prod-
ucts, administered simultaneously [5]. Because this was a
cross-over study, the patients were used as their own con-
trol. The generic FDC was proven to be bioequivalent to
the administration of the three branded formulations of
d4T, 3TC and NVP [5].
In a cross sectional study to evaluate the LPV minimum
concentration (Cmin) in Thai HIV-1 infected adults using
the Matrix LPV/r generic tablet version, it was found that
patients had a median (IQR) LPV Cmin of 7.2 (5.8-8.3) mg/
l, which was well above the LPV therapeutic level of 1.0
mg/l [6]. In another PK study from Thailand, the Matrix
generic LPV/r was bioequivalent to the pediatric branded
tablets (LPV/r 200/50 mg, Abbott) in adults with HIV
infection [7]. This study utilized pediatric instead of adult
branded tablets as Abbott has not marketed this product
in Thailand in response to the Thai Government's com-
pulsory licensing policy [6].
Safety, efficacy and tolerability of generic ART in adults
In Thailand, the Government Pharmaceutical Organiza-
tion (GPO) began producing several antiretroviral drugs
in 1995, but it was not until 2002, when GPO produced
its first FDC of stavudine (d4T), lamivudine (3TC) and
nevirapine (NVP) (GPO-VIR-S®) that HIV in Thailand
changed from a deadly disease into a manageable chronic
d i s e a s e  [ 8 ] .  I n  p a t i e n t s  w i t h  a d v a n c e d  H I V  i n f e c t i o n
(CD4 count of less than 100 cells/mm3 at baseline), the
GPO-VIR-S® combination had good efficacy, with 63.7%
of patients showing plasma HIV-RNA of less than 50 cop-
ies/ml after 48 weeks of treatment [8]. The median
decline in plasma HIV RNA from baseline was 3.8 log10
copies/ml (range 0.2-2.4) at week 48, which is comparable
to the results of the 2NN study, in which 65.4% of the
patients on (branded) d4T/3TC/NVP achieved virologi-
cal suppression after 48 weeks [9]. A second study assess-
ing the efficacy of the GPO-VIR-S® combination had a
median follow up period of 15 weeks, during which 54%
of the patients achieved virological suppression [10].
These results demonstrate the effectiveness of the generic
FDC d4T/3TC/NVP.
The effectiveness and safety of the FDC of TDF/emtric-
itabine (FTC)/efavirenz (EFV) was illustrated in HIV
infected adults in western India [11]. Both ART-naïve and
-experienced patients showed excellent immunological
and virological response and adherence. None of the
patients in this study experienced clinical or immunologi-
cal failure, and the median change in CD4 count after 12
months was +368 cells/mm3  among the ART-naïve
patients and +176 cells/mm3  among the ART-experi-
enced patients. Similarly, the virological response was
high: 96% of all patients had plasma HIV-RNA less than
400 copies/ml after 6 months. The most common toxicity
experienced was EFV related neuropsychiatric com-
plaints; grades 1 and 2 in 16 patients, and 1 patient (0.7%)
had to discontinue the regimen due to grade 4 neuropsy-
chiatric toxicity. This rate is lower than those reported in
developed countries [12,13]. However, the grades 3 and 4
renal toxicity was higher than in the published literature
with 4 patients (2.8%) discontinuing the regimen [12,14].
This renal toxicity was likely from TDF and it was mainly
found in patients with pre-existing renal disease.
However, the first line generic ART being used in
resource-limited settings, mainly d4T-based regimens,
have been associated with adverse events. HIV infected
patients who had completed a minimum of 3 months of
first line generic highly active antiretroviral therapy
(HAART) in India were followed for a total of 6504 per-
son years to assess the spectrum of adverse events [15].
The majority of patients (75%) were on a d4T-containing
regimen and 53.4% developed at least one adverse event
(most commonly rash 15.2%, peripheral neuropathy 9.0%,
and anemia 5.4%) and 46.3% of these patients conse-
quently changed or discontinued their regimen. Studies
in developed countries have also identified toxicity as a
major reason for regimen changes or discontinuation; a
study from the United States reported that 47% of discon-
tinuations were due to toxicity [16], and in the Swiss HIV
Cohort study 46.6% of the treatment modifications in the
first year after starting HAART were due to toxicity [17].
Sivadasan et al. however , reported a much higher rate:
68.1% of the changes in first line generic antiretroviral
r e g i m e n s  i n  t h e i r  c o h o r t  i n  S o u t h  I n d i a  w e r e  d u e  t o
WHO grade 3 and 4 toxicity [18]. The most common tox-
icities were lactic acidosis in 20 (32.3%) patients, severe
anemia in 16 (25.8%) patients and polyneuropathy in 12
(19.4%) of the patients. In this cohort, 76% of the patients
were started on a d4T-containing regimen. Moreover,
70% of the patients had WHO clinical stage 3 or 4 before
starting HAART. In the multivariate analysis, advanced
HIV disease was one of the predictors for regimen
change, together with current smoking, body mass index
of more than 25 kg/m2  and baseline elevated liver
transaminases. More importantly to note is that lactic
acidosis, severe anemia and polyneuropathy are all
caused by the thymidine-analogue nucleoside reverse
transcriptase inhibitors (NRTI) d4T and AZT. Current
Western guidelines recommend the use of a TDF-based
regimen for first line [19,20], and as a result d4T and AZTRamautarsing and Ananworanich AIDS Research and Therapy 2010, 7:18
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are used less and less in developed countries. The 2010
WHO guideline now recommends the use of TDF or
AZT in the first line, and to avoid the use of d4T due to
"the disfiguring, unpleasant and potentially life threaten-
ing toxicity of d4T" [21]. The high cost of TDF however,
remains a barrier to the implementation of TDF as first
line in resource limited settings. This underscores the
need to make effective and safe generic TDF-based regi-
mens for wide distribution in developing countries. In
light of the current cuts in worldwide funding programs
that provide antiretrovirals (ARVs) for millions of HIV
patients in resource limited countries, it has been sug-
gested to look into the potential of reducing the d4T dose
in order to decrease toxicity, while maintaining virologi-
cal efficacy [22]. This will be discussed in more detail
below.
Safety, efficacy and tolerability of generic ART in children
An estimated 3 million children are currently infected
with HIV, and in 2008, only 38% of those children who
were in need of HIV treatment had access to and were
treated with ART [1]. Children are an extremely vulnera-
ble group. Due to an immature immune system, the
course of disease in children is extremely aggressive. Scal-
ing up access to pediatric treatment has been slow, and
there are a number of reasons for this, e.g. a lack of focus
on HIV infected children by many governments, higher
cost for pediatric formulations (50-90% higher than adult
versions for branded products), a lack of ARV formula-
tions for use in children, a lack of appropriate strength
tablets, limited liquid formulations, a lack of pediatric
labeling for many ARVs and difficulty gaining registration
in many countries. Many studies have shown that chil-
dren in resource limited settings respond as well to ART
as children in resource rich settings [23]. Puthanakit et al.
assessed the long term rates of viral suppression and
immune recovery in 107 ART naïve Thai children with
advanced HIV infection [24]. After four years of treat-
ment 70% of the children had plasma HIV-RNA below 50
copies/ml, and the mean CD4-percentage increased from
5.3% at baseline to 26.6%, demonstrating the long term
effectiveness of HAART in a resource limited setting.
An emerging problem however, is the development of
first line treatment failure in children. Of the children
enrolled in the Therapeutics, Research, Education and
AIDS Training in Asia (TREAT Asia) program, 20% were
on their second ARV regimen [25]. In China's National
Pediatric ART Program 27.5% of the ART-naïve children
and 62.5% of the ART experienced children showed resis-
tance to one or more drugs after one year of treatment
[26]. These numbers are worrisome, as evidence-based
studies guiding the management of treatment failure in
children are lacking, and the number of second line ARVs
available for children, as well as the access to these medi-
cations, are limited [27]. For children who failed a 2NRTI
plus a non-nucleoside reverse transcriptase inhibitor
(NNRTI) regimen, a boosted protease inhibitor (PI) regi-
men is preferred [28]. Due to its high cost, the access to
PIs is still limited for pediatric treatment. To address this
issue, Puthanakit et al. assessed the LPV plasma concen-
trations in Thai HIV-infected children being treated with
the adult tablet formulation of the Matrix generic LPV/r,
and compared these to the LPV plasma concentrations
during treatment with the branded soft gel capsule (SGC)
formulation in the same patients [29]. The adult generic
tablet, administered as the whole tablet, or in fractions,
resulted in a median (IQR) LPV Cmin of 6.7 (5.0-9.9) mg/l,
which was comparable to the LPV Cmin after treatment
with the SGC, 7.3 (4.4-9.8) mg/l, P = 0.87. Importantly,
24% of the children had LPV Cmin higher than 10 mg/l,
which is a particular concern; given that long term expo-
sure to high concentrations of LPV may be a risk for dys-
lipidemia [30]. Two other studies in Thailand have also
highlighted the issue of elevated PI plasma concentra-
tions in Thai children. Bunupuradah et al. described rela-
tively high plasma levels of saquinavir and LPV , and an
increase in lipids after 96 weeks of double boosted PI
(saquinavir/LPV/r) treatment in pre-treated HIV infected
children [31]. Furthermore, Plipat et al. reported that a
reduced dose of indinavir (IDV) boosted with ritonavir
leads to adequate IDV plasma concentrations in pre-
treated HIV infected children [32]. Further studies to
assess the long-term safety and efficacy of reduced dose
PIs and its potential to reduce toxicity and cost are
needed.
ART Dose reduction
The majority of the dose finding studies has been con-
ducted in Caucasian men, and often relatively high ARV
doses have been used to avoid sub-therapeutic levels. Evi-
dence indicating that Asian patients have higher plasma
concentrations for several ARVs compared to Caucasians
is mounting. Genetic differences between ethnicities may
be the primary cause for altered drug metabolism, and as
a result, different PK parameters. Here we describe the
dose reduction studies for different ARVs (Table 1).
NRTIs
NRTI dose reductions are proven to be safe and effective.
Dose reduction of d4T to 20 mg twice daily for patients
with body weight less than 60 kg and 30 mg twice daily
for patients with body weight more than 60 kg has been
shown to be effective, with a more favorable toxicity pro-
file [22,33]. Furthermore, AZT 300 mg twice daily, which
is the recommended dosage, results in a 5-fold increases
in plasma AZT concentrations in Thais [34]. Dose reduc-
tion from AZT 300 mg to 200 mg twice daily in Thais
who weigh less than 60 kg resulted in comparable AZTRamautarsing and Ananworanich AIDS Research and Therapy 2010, 7:18
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plasma concentrations as AZT 300 mg twice daily in Cau-
casians with a mean weight of 74 kg [35].
NNRTIs
Efavirenz (EFV)
Most of the Asian studies that assess the PK parameters
of EFV have been conducted in patients taking rifampicin
at the same time. EFV plasma concentrations can be
reduced when co-administered with rifampicin [36] and
in the past, an increase from EFV 600 mg to 800 mg once
daily has been suggested when co-administering with
rifampicin. A study in Thailand comparing EFV 600 mg
with EFV 800 mg in patients using rifampicin showed
that EFV plasma concentrations were similar [37], with
excellent virological and immunological responses in
both groups after 48 weeks [38] suggesting that Thai
patients have sufficient EFV plasma concentrations even
in the presence of rifampicin. Currently however, there is
no consensus about the need to increase EFV dosage dur-
ing rifampicin treatment; the WHO and United States
Department of Health and Human Services guidelines do
not recommend a dose increase, whereas the European
AIDS Clinical Society does [19-21]. In Thai patients not
taking rifampicin, EFV plasma concentrations were com-
pared between EFV 400 mg once daily and EFV 600 mg
once daily in the same patients. The 400 mg once daily
dose resulted in, significantly lower, but still adequate
plasma concentrations compared to the 600 mg once
daily dosing, again demonstrating that Thai patients gen-
erally have higher plasma concentrations of several ARVs
and that dose reduction does not compromise the effi-
cacy [39].
EFV plasma concentrations are highly variable, and this
variability may largely be depended on genetic variation
of the gene that encodes the CYP450-2B6 isoenzyme.
This isoenzyme is responsible for the 8-hydroxylation of
EFV and for about 90% of its clearance. Individuals with a
heterozygous or homozygous 516G > T polymorphism
have significantly higher EFV concentrations compared
to individuals with the wild-type polymorphism [40].
Puthanakit et al. demonstrated that the children in their
cohort had adequate EFV plasma concentrations [41] and
Table 1: Summary of dose reduction for Antiretrovirals
Drug Recommended dose Reduced doses with supportive PK/short term efficacy data
NRTIs
d4T [22,33] 30 mg BID 30 mg when > 60 kg
20 mg when < 60 kg
AZT [34,35] 300 mg BID 200 mg BID
NNRTIs
EFV [39] 600 mg OD 400 mg OD
NVP when co-administered with rifampin [44] Not recommended 400 mg BID
PIs
IDV/r [45] 800/100 mg BID 400/100 mg BID
SQV/r [46-48] 1000/100 mg BID 1600 or 1500/100 mg BID




LPV/r during 3rd trimester of pregnancy [60] 600/150 mg BID 400/100 mg BID
NRTIs: nucleoside reverse transcriptase inhibitors. NNRTIs: non-nucleoside reverse transcriptase inhibitors. PIs: protease inhibitors. BID: twice 
daily. OD: once daily, PK: pharmacokineticRamautarsing and Ananworanich AIDS Research and Therapy 2010, 7:18
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there was a strong correlation between the CYP2B6-
516G > T polymorphism and EFV plasma concentra-
tions.
Nevirapine (NVP)
Rifampicin reduces the nevirapine area under the curve
(AUC) by 20 to 58% [19,42] and Western guidelines rec-
ommend not to use this combination in HIV-tuberculosis
co-infected patients [19,20]. However, NVP is still the
NNTRI of choice in many developing countries, since it is
widely used in the majority of FDCs. Thai patients receiv-
ing a NVP-based HAART regimen with rifampin had
their mean plasma NVP concentrations compared to
Thai patients receiving NVP-based HAART without
rifampin [43]. Even though the plasma concentrations in
the rifampin group were considerably lower than in the
group without rifampin, the great majority (86%) had
adequate NVP plasma concentrations. In another study
from Thailand, patients using rifampicin were random-
ized to NVP 400 mg per day or NVP 600 mg per day [44].
The results indicated that 400 mg per day had a similar
efficacy as 600 mg, but the patients receiving 600 mg per
day were more likely to experience adverse events related
to NVP. Therefore, dose increase during rifampin treat-
ment is not recommended in Thai patients [44].
Protease Inhibitors - PIs
Indinavir (IDV)
The recommended dose for IDV boosted with Ritonavir
(RTV) is 800/100 mg twice daily. However, the use of IDV
is highly associated with renal toxicity, especially in
patients with IDV AUC of higher than 60 h*mg/l. In Thai
HIV infected patients, a reduced dose of IDV/r 400/100
mg twice daily is effective and well tolerated [45]. In that
study, the median (IQR) of IDV Cmin was 0.17 (0.12-0.30)
mg/l and 80% of the patients had IDV concentrations
above the therapeutic level of 0.10 mg/l.
Saquinavir (SQV)
SQV/r is dosed as 1000/100 mg twice daily. A study com-
paring the PK parameters of three different dosages in
Thai patients (SQV/r 1600/100 mg once daily, 1000/100
mg twice daily and 2000/100 mg once daily) found that
both 1000/100 mg twice daily and 2000/100 mg once
daily resulted in a higher AUC and Cmin compared to
1600/100 mg once daily [46]. However, the mean Cmin of
all three were higher than the recommended Cmin of 0.1
mg/l. Furthermore, SQV/r 1600/100 mg once daily was
shown to have strong antiviral efficacy when used with an
NRTI backbone in Thai HIV-infected patients [47,48]. In
a study comparing SQV 600 mg with SQV 1000 mg twice
daily, co-administered with either LPV/r 400/100 twice
daily or 266/66 mg twice daily in Thai ARV naïve
patients, SQV dose reduction to 600 mg resulted in ade-
quate PK parameters, with a higher SQV AUC when co-
administered with LPV/r 400/100 mg compared to LPV/r
266/66 mg [49]. With accumulating pharmacokinetic
data indicating dose reduction is safe and effective, SQV
is now recommended at 1500 (or 1600 mg) once daily, co-
administered with RTV 100 mg once daily in the treat-
ment of ART-naive Thais.
In children who failed an NRTI/NNRTI based HAART
regimen, a double boosted PI regimen (SQV and LPV/r)
was demonstrated to have strong virological and immu-
nological response after 48 weeks and 96 weeks [31,50].
However, as mentioned before, the Cmin of both PIs were
higher than the therapeutic concentrations, resulting in
elevated lipids and suggesting further exploration of the
possibility of dose reduction of PI in children.
Atazanavir (ATV)
ATV can be dosed once daily. It has a low pill burden and
a good toxicity profile, and is one of the preferred PI
choices in guidelines [19,20]. ATV levels are boosted by
RTV. The standard once daily dose of ATV is 400 mg
without RTV boosting in treatment naïve patients and
300 mg ATV with 100 mg RTV boosting in treatment
experienced patients. The dose reduction of ATV/r from
300/100 mg once daily to 200/100 mg once daily in Thai
adults has been investigated. The lower 200/100 mg once
daily dosing showed lower, but still adequate PK parame-
ters, and none of the patients had an ATV Cmin lower than
the therapeutic level of 0.15 mg/l [51]. After dose reduc-
tion, there was a significant reduction in serum bilirubin.
In a smaller study, also in Thailand, 14 patients who were
treated with ATV/r at 200/100 mg once daily had good
virological and immunological responses after 68 weeks
[52].
Lopinavir (LPV)
In Asia, LPV/r is the PI that is most used as part of sec-
ond line regimens. The recommended dose is LPV/r 400/
100 mg twice daily. The original formulation, the soft gel
capsule (SGC, 133.3/33.3 mg) needs to be taken with
food, and requires refrigerated storage. More recently, a
tablet formulation has been developed (200/50 mg), and
it has better bioavailability and no food or refrigerated
storage requirements. A lower dose of LPV/r at 266/66
mg twice daily used together with SQV displayed ade-
quate LPV PK parameters in adults [49]. Similarly in a
pediatric study, Thai HIV-infected, PI-naïve children
were treated with either the WHO recommended dose of
LPV/r or 70% of the standard dose, with 2 NRTI back-
bone [53]. The PK parameters of LPV and RTV were not
significantly different in both groups, and after 48 weeks
the safety and efficacy were excellent.
Because an earlier study showed evidence for high Cmin
in Thais using generic LPV/r [6], a subsequent study by
the same group of investigators evaluated the PK of twice
daily LPV/r reduced dose (200/50 mg twice daily) as well
as the PK of the generic versus the branded LPV/r. TheyRamautarsing and Ananworanich AIDS Research and Therapy 2010, 7:18
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found that generic LPV/r had an equivalent PK profile as
the branded product, however, the reduced LPV/r dose of
200/50 mg twice daily had inadequate LPV PK parame-
ters [7]. This was most likely because a reduction of the
RTV dose by 50% was inadequate to boost LPV plasma
concentrations. In contrast to IDV, SQV and ATV, LPV
levels appear to be highly dependent on the amount of
RTV [54]. Reduced dose of LPV combined with a higher
dose of RTV (e.g. LPV200mg/RTV100mg) could possibly
result in adequate LPV levels and should be further inves-
tigated.
In pregnant women, the metabolism of several drugs is
altered due to a change in the physiology, particularly the
expansion of intravascular volume and the induction of
the hepatic CYP 450 system that leads to higher rates of
drug metabolism [55,56]. Both can lead to insufficient
drug levels, especially in the third trimester [57]. An
increase in the LPV/r dose is recommended in the third
trimester [58], but guidelines have not yet adapted this
recommendation, and state that data are not yet conclu-
sive as to the optimal dose during pregnancy [59]. A PK
study was done in Thai HIV-infected pregnant women
who were using the standard dose of 400/100 mg twice
daily [60]. PK curves were recorded at gestational age 20
weeks (GA20), GA 33 and 12 weeks post-partum (12PP).
Twelve women recorded both the GA33 and the 12PP
curve; the mean LPV AUC was significantly lower at
GA33 compared to 12PP. At GA 33, 95% of the women
had sufficient LPV plasma concentration above 1.0 mg/l
and at 12PP all women had LPV plasma concentration
above 1.0 mg/l, indicating that Thai HIV-infected preg-
nant women do not require a LPV/r dose increase during
the third trimester of pregnancy. This highlights the
needs to conduct studies in different ethnic groups as
guidelines developed based on Caucasian PK data cannot
be extrapolated to other ethnicities.
Conclusions
The data summarized in this review underscores the
need to explore alternative options to scale up ART for
resource limited settings, particularly safe and effective
generic ART, and dose reduction of ART. Current evi-
dence support the bioequivalence, safety and efficacy of
generic ART compared to branded products. More effort
is needed to scale up generic FDCs using drugs with
favorable toxicity profiles such as TDF-based regimens
for first and second line regimens. Data on ART dose
reduction, mainly from small PK studies in Thailand, sug-
gest that reduced doses of ART do not compromise PK
parameters, and short term safety and efficacy. This war-
rants larger randomized studies to evaluate the efficacy of
reduced dose ART. Such effort is underway for low dose
EFV 400 mg once daily as first line ART (ENCORE study,
clinicaltrials.gov NCT01011413).
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